Congress Presentation presented at AHA 2017 given by Dr. Chris Cannon with slides on a neutral background ( only Study branding) Including Q&A with Dr. Cannon and Dr. Hohnloser on FAQs related to the study results as well as the clinical implications of the results. Q&A 1: What may be the implication of the RE-DUAL […]
Why do heart doctors care so much about your legs? How can a cardiologist care for your whole body? What is an interventional cardiologist in the first place? In this video, Dr. Daniel Ice, MD answers all of these questions and more.
Safety of uninterrupted dabigatran for cardiovascular interventions in the GLORIA-AF Registry Program (summarized by Prof Gregory Lip). An educational video summarizing data presented at EHRA, Barcelona 2018.
Expert interview with Dr. Jur ten Berg about dual antithrombotic therapy with Dabigatran in AF patients post PCI. In the interview he focuses mainly on new subanalyses, presented at ACC Does the Discontinuation of ASA in the Warfarin-TT Arm Influence the Treatment Outcomes Vs Dabigatran-DT? Landmark analysis What treatment regimens were compared in the RE-DUAL […]
Interview series with Professor Stefan Hohnloser about dual antithrombotic therapy with Dabigatran in AF patients post PCI Should dabigatran dual therapy be the default strategy for most patients with AF and ACS? Which dabigatran dose would be recommended for patients with AF and ACS Post-PCI? How do the data reported on concomitant use of ticagrelor […]
Dr. Dominick Angiolillo summarizes the results of the RE-DUAL PCI study showing the safety of dabigatran dual therapy post-PCI with doses approved for stroke prevention in AF. He also shows data on subgroup analysis in patients with ACS / no ACS as an index event and subgroup analysis looking at results dependent on the P2Y12 […]